Login to Your Account

Post negative ODAC vote, Clovis scrubs rociletinib program, plans staff cuts

By Michael Fitzhugh
Staff Writer

Friday, May 6, 2016

Anticipating an FDA CRL for rociletinib, Clovis Oncology Inc. quit enrolling ongoing studies of the drug, withdrew its European marketing authorization application filing and expects to trim its headcount by 35 percent from its 2015 level by year-end.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription